【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 What Is This Report About? 8
3 Definitions of Markets/Categories Covered 9
3.1 Drug Delivery Devices 9
3.1.1 Metered Dose Inhaler Devices 9
4 Company Snapshot 10
4.1 Key Facts 10
4.2 Company Overview 10
4.3 SWOT Snapshot 10
5 Business Description 11
5.1 Business Overview 11
5.2 Animal Health 11
5.2.1 Overview 11
5.2.2 Financials 11
5.2.3 Market View 11
5.3 Human Pharmaceuticals 12
5.3.1 Overview 12
5.3.2 Financials 12
5.3.3 Market View 12
5.4 Human Pharmaceuticals 12
5.4.1 Overview 12
5.4.2 Financials 12
5.4.3 Market View 12
5.5 Major Products and Services 13
5.5.1 Overview 13
6 History 15
7 Business Strategy 21
7.1 Mission Statement 21
8 SWOT Analysis 22
8.1 Overview 22
8.2 Boehringer Ingelheim GmbH Strengths 22
8.2.1 Delivering Value through Innovation 22
8.2.2 Geographical Diversity 23
8.2.3 Contract Manufacturing Capabilities 23
8.2.4 Broad Product Portfolio 23
8.3 Boehringer Ingelheim GmbH Weaknesses 24
8.3.1 Pradaxa Lawsuit 24
8.3.2 Product Recalls 24
8.4 Boehringer Ingelheim GmbH Opportunities 24
8.4.1 Strategic Alliances 24
8.4.2 Market Growth in Emerging Economies 24
8.4.3 Growing CRO Industry 25
8.5 Boehringer Ingelheim GmbH Threats 25
8.5.1 Increased Scrutiny on Imports 25
8.5.2 Stringent Government Regulations 25
8.5.3 Uncertain R&D Outcomes 25
8.5.4 Cost Containment Pressures 26
9 Competitors 27
10 Competitive Landscape 28
10.1 Drug Delivery Devices (Metered Dose Inhaler Devices), Global, Market Share (%), 2011 28
10.2 Boehringer Ingelheim GmbH, Market (Metered Dose Inhaler Devices), by Region, Market Share (2011) 29
10.3 Boehringer Ingelheim GmbH, Drug Delivery Devices (Metered Dose Inhaler Devices), by Country, Market Share (2011) 30
11 Key Employees 32
12 Key Employee Biographies 33
13 Company Statement 34
14 Locations And Subsidiaries 35
14.1 Head Office 35
14.2 Other Locations & Subsidiaries 35
15 Financial Deals Landscape 36
15.1 Boehringer Ingelheim GmbH, Deals Volume Summary, 2007 to YTD 2013 36
16 Boehringer Ingelheim GmbH Detailed Deal Summary 38
16.1 Partnerships 38
16.1.1 BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim 38
16.2 Equity Offering 39
16.2.1 Vectura Group Completes Private Placement Of $7.22 Million 39
16.2.2 Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million 40
17 Recent Developments 41
17.1 Strategy And Business Planning 41
17.1.1 Sep 17, 2012: Boehringer Ingelheim To ShutDown One API Plant In Petersburg, Virginia 41
17.1.2 Sep 10, 2012: Boehringer Ingelheim Implements Flexible Fully Disposable Up- And Downstream Manufacturing For Biopharmaceuticals 41
17.1.3 Jun 18, 2012: Boehringer Ingelheim Sets Up Distinctive Brand For Biopharmaceutical Contract Manufacturing Business 41
17.1.4 May 31, 2012: Boehringer Ingelheim Expands Development Capacities With New Technical Center 42
17.1.5 Mar 12, 2012: Boehringer Ingelheim Sets Up First Asian Veterinary Research & Development Center In Shanghai 42
17.1.6 Dec 14, 2011: Boehringer Ingelheim Significantly Expands Supply Center For China 43
17.1.7 Sep 26, 2011: Boehringer Ingelheim Expands Business With Biosimilars 44
17.1.8 Jun 20, 2011: Boehringer Ingelheim Expands New Service With New Fill And Finish Capabilities 44
17.1.9 Feb 15, 2011: Pfenex And Boehringer Ingelheim Sign Non-Exclusive Strategic Agreement For Use Of Pfenex Expression Technology 44
17.1.10 Nov 27, 2009: Boehringer Ingelheim, Vectura Terminate Collaboration 45
17.1.11 Nov 09, 2009: Evotec Extends Research Collaboration With Boehringer Ingelheim 45
17.1.12 Oct 22, 2009: Evotec Obtains E2.5m Milestone Payment From Boehringer Ingelheim 45
17.1.13 Jun 15, 2009: Boehringer Ingelheim, Vitae Collaborate For Development Of Beta-Secretase Inhibitors 46
17.1.14 May 29, 2009: Boehringer Ingelheim, DxS Sign Collaboration Agreement 46
17.1.15 Jun 17, 2008: Boehringer Ingelheim To Acquire Actimis Pharmaceuticals 46
17.1.16 Apr 19, 2006: Vectura Enters Agreement With Boehringer Ingelheim 47
17.2 Financial Announcements 48
17.2.1 Aug 14, 2012: Boehringer Ingelheim Achieves Growth In H1 2012 48
17.2.2 Apr 24, 2012: Boehringer Ingelheim Reports Net Sales Of €13.2 Billion In 2011 49
17.2.3 Aug 09, 2011: Boehringer Ingelheim Reports Net Sales Of €6.4 Billion For H1 2011 49
17.2.4 Jul 28, 2009: Boehringer Ingelheim Posts First Half Financial Results 50
17.2.5 Aug 07, 2008: Boehringer Reports 1H 2008 Results 51
17.2.6 Jul 26, 2007: Boehringer Declares H1 2007 Results 52
17.3 Research And Development 53
17.3.1 Sep 19, 2012: Ten Pharmaceutical Companies Unite To Accelerate Development Of New Medicines 53
17.3.2 Jul 09, 2012: Boehringer Ingelheim Establishes Translational Research Collaboration With Harvard University In Areas Of Unmet Medical Need 54
17.3.3 Feb 29, 2012: Boehringer Ingelheim Expands Capabilities In Biopharmaceutical Process Science 54
17.3.4 Feb 03, 2012: Boehringer Ingelheim, GWT And TU Dresden Sign Diabetes Research Collaboration 55
17.3.5 Jan 17, 2012: CompleGen Announces Successful Delivery Of XenoGene Technology To Boehringer Ingelheim Under Non-Exclusive Agreement 56
17.3.6 Jan 05, 2012: FORMA Therapeutics Announces Collaboration With Boehringer Ingelheim For Development Of New Oncology Drugs 56
17.3.7 Feb 16, 2011: Québec Consortium for Drug Discovery Launches New Explore Program To Drive Innovation 56
17.3.8 Nov 22, 2010: f-star And Boehringer Ingelheim Partner To Develop New Therapeutic Antibodies 57
17.3.9 Oct 26, 2010: Boehringer Ingelheim Partners With MacroGenics To Discover, Develop And Commercialize DART-Based Antibody Therapeutics 57
17.3.10 Aug 26, 2010: Boehringer Ingelheim Opens Center of Competence In Shanghai 58
17.4 Corporate Communications 59
17.4.1 Jun 26, 2008: Boehringer Ingelheim Announces Board Changes 59
17.5 Government and Public Interest 60
17.5.1 Sep 12, 2012: Common Application For HIV Patient Assistance Program Expedites Application Process For Lifesaving Drugs 60
17.5.2 Oct 23, 2009: EMEA Issues Positive Opinion For Micardis 61
17.5.3 Oct 14, 2009: Boehringer Ingelheim Receives Marketing Authorisation From European Commission For Mirapexin/Sifrol 61
17.5.4 Oct 07, 2009: Astellas, Boehringer Ingelheim Reach Settlement With Impax 62
17.6 Product News 62
17.6.1 Oct 01, 2012: Boehringer Ingelheim’s New Project Transfer Program Enables Fast Track To Launch For Biopharmaceuticals 62
17.7 Other Significant Developments 63
17.7.1 Oct 26, 2012: Boehringer Ingelheim To Invest €85m In Dortmund Facility To Double Respimat Production 63
17.7.2 Apr 25, 2012: Boehringer Ingelheim Standardizes All Prescription Medicine Commercial Teams Worldwide On Cloud-Based, Veeva CRM And iRep 63
17.7.3 Apr 20, 2012: Boehringer Ingelheim Launches GLORIA-AF Registry Program To Investigate Use Of Antithrombotic Therapy 64
17.7.4 Jan 26, 2012: Boehringer Ingelheim Launches Lean-to-Clinic Program For Fast Drug Product Supply 65
17.7.5 Oct 20, 2011: Patheon Signs Three Year $18m Development Agreement With Boehringer Ingelheim 65
18 Appendix 66
18.1 Research Methodology 67
18.2 Secondary Research 67
18.3 Primary Research 67
18.4 Models 68
18.5 Forecasts 68
18.6 Expert Panels 68
18.7 GlobalData Consulting 68
18.8 Currency Conversion 69
18.9 Contact Us 70
18.10 Disclaimer 70
【レポート販売概要】
■ タイトル:Boehringer Ingelheim GmbH:市場シェア分析■ 英文:Boehringer Ingelheim GmbH Market Share Analysis
■ 発行日:2013年1月31日
■ 調査会社:GlobalData
■ 商品コード:GDATA403160221
■ 調査対象地域:グローバル
- Quantel Medical SA:市場シェア分析Quantel Medical SA Market Share Analysis Summary GlobalData’s new report, “Quantel Medical SA Market Share Analysis” provides in-depth information on Quantel Medical SA’s market position in the different medical equipment markets it operates in. The report provides Quantel Medical SA market share information in two key market categories – Ophthalmic Diagnostic Equipment and Refractive Surgery Devi …
- エチレンオキシド及びエチレングリコールの世界市場2016-2020About Ethylene Oxide and Ethylene Glycol Ethylene oxide is a chemically reactive material. It is used for manufacturing ethylene glycols, glycol ethers, ethanolamines, surface-active agents, and polyether polyols. Ethylene glycol is a clear, viscous, versatile organic compound that is a hydroscopic liquid at room temperature. It is used in the manufacture of polyester films, fibers and PET resins, …
- レーダーセンサーの世界市場2019-2023About this market The growing adoption of radar sensors in several applications will drive the market growth in the forthcoming years. Owing to the adoption of radar sensors in logistics, traffic management, industrial, automotive, and smart home applications, the need for radar sensors is likely to surge considerably in the forthcoming years. Increasing penetration of smart homes will further res …
- 血液凝固分析装置の世界市場The global coagulation analyzers market is estimated to grow at a lower CAGR in developed countries; however, it is expected to witness high growth in emerging countries such as China, India, and Brazil in the next five years. Growth in the coagulation analyzers market is driven by factors such as increasing adoption of automated hemostasis instruments by diagnostics laboratories, development of h …
- データセンター・ファブリックのグローバル市場動向(2014 – 2019)Data center fabric is emerging as an efficient solution over the traditional and legacy networking solutions in today’s data centers. Data center fabric improves the functioning of data centers for increasing profit margin of organizations. Fabric simplifies the traditional complex network architecture of data centers. Switches and routers comprise the major part of data center fabric products. Mo …
- 胃酸過多/胸やけ/呑酸(Acid Indigestion / Heartburn/ Pyrosis):世界の治験レビュー(2015年上半期版)Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2015" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartbur …
- Great Plains Energy Incorporated:石油・ガスバリューチェーン分析レポート2013Great Plains Energy Incorporated Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Great Plains Energy Incorporated" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Great Plains Energy Incorporated”. The report provides key information relating to oil and gas assets of the company along with its operations acr …
- クラウド・アクセス・セキュリティ・ブローカーの世界市場MarketsandMarkets forecast the cloud access security brokers market size to grow from USD 3.34 Billion in 2015 to USD 7.51 Billion by 2020, at a compound annual growth rate (CAGR) of 17.6%. The major drivers of cloud access security broker include control data loss, real-time monitoring capabilities, and increasing adoption of cloud-based applications. The cloud access security brokers enable ente …
- モバイルクーポンの世界市場2016-2020About Mobile Coupons A mobile coupon refers to the electronic ticket that is solicited or delivered by the cell phone that can be exchanged for a financial discount or rebate while making a purchase of a product or service. Generally, the coupons are issued by the manufacturers of customer packed goods and services. Mobile coupons are basically issued by the manufacturers of customer packed goods …
- Esophageal Achalasia:グローバル臨床試験レビューH1, 2013Esophageal Achalasia Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Esophageal Achalasia Global Clinical Trials Review, H1, 2013" provides data on the Esophageal Achalasia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Esophageal Achalasia. It includes an overview of the trial numbers and their r …
- Diabetic Peripheral Neuropathy:治療薬のグローバル治験動向(2014年上半期)Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Peripheral Neuropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Peripheral Neuropathy. It includes an o …
- Diabetic Foot Ulcers:市場分析及び予測(~2017)OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2017 Summary Diabetic foot ulcers (DFUs) are a common complication of diabetes, and with the increasing prevalence of diabetes across all markets, the number of patients suffering from DFUs is also expected to rise. Despite the availability of various treatment modalities, there are currently few advanced wound care p …
- キレート剤の世界市場:アミノポリカルボキシレート、リン酸塩、ホスホン酸The global chelating agent market, in terms of value, is projected to reach USD 6.18 Billion by 2021, at a CAGR of 4.12% from 2016 to 2021. High-growth application areas such as pulp & paper, cleaners, water treatment and personal care and extensive new product launch and agreement & collaboration activities by companies are key factors driving the global chelating agents market. The chelating age …
- 輪転グラビア印刷用インクの世界市場:ニトロセルローズ、ポリアミド、ポリウレタン、アクリルThe global market size of rotogravure printing inks is projected to reach USD 4.30 Billion by 2021, registering a CAGR of 4.99% between 2016 and 2021. The growing manufacturing and end-use industries and the increasing flexible packaging application is driving the demand for rotogravure printing inks in the Asia-Pacific region and also the continuous product development, expansion, and merger & ac …
- 世界のPasta & Noodles市場におけるニュース・イベント動向(2014年2月)Synopsis The report provides a review of the latest news and key events in the global pasta & noodles market during February 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global pasta & noodles market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events …